Berenberg has lowered its recommendation on Givaudan SA to Hold from Buy and cut its price target to CHF2,915 from CHF3,580, reflecting weaker expectations for organic sales growth tied to exposure in the Middle East.
The investment bank now sees the group’s organic growth slowing into the second quarter of 2026, with quarterly growth forecasts of 2.0% in Q1 and 1.8% in Q2 before a recovery to 2.8% in the second half. Berenberg’s revised outlook reduces full-year organic sales growth to 2.3%, down from a prior forecast of 3.4%.
Analyst rationale and regional exposure
Berenberg identifies exposure to the Middle East as a principal driver of the downgrade. The region accounts for roughly 8% of Givaudan’s group sales and a little more than 10% of its Fragrance & Beauty division. Within that division, the Fine Fragrances segment is singled out as the most vulnerable to the regional disruption.
Fine Fragrances made up 12% of group revenue in 2025 and contributed 38% of the company’s organic sales growth that year. The unit grew 18% organically in 2025, but Berenberg estimates around one-fifth of Fine Fragrances sales are linked to the Middle East. The bank highlights recent weakness in perfume retail sales across the GCC, which it says have fallen in the 20%–25% range since early March, compared with a prior trend of about 10% growth.
Other categories in the Fragrance & Beauty division - including laundry detergents, hair care and body care - are expected to face some impact as well, although demand for these categories is described as comparatively more resilient than discretionary perfume purchases.
Updated financial outlook
Berenberg modestly reduced its 2026 earnings per share estimate by 0.4%, citing the weaker sales outlook while noting partial offset from favourable foreign-exchange movements. The bank also raised its weighted average cost of capital assumption to 8.6% from 7.5%.
On a line-by-line basis, the bank expects Givaudan to record sales of CHF7.40 billion in 2026, down from CHF7.47 billion reported in 2025. Adjusted EBIT is forecast at CHF1.43 billion and adjusted net income at CHF1.10 billion. Adjusted EPS is projected at CHF119.66 for 2026, versus CHF121.17 in 2025.
Margins are expected to remain largely stable under the revised forecast: an EBITDA margin of 24.3% in 2026 compared with 24.2% in 2025, and an EBIT margin of 19.3% versus 19.2% the prior year. Net income margin is projected to be 14.9%, down slightly from 15.0%.
Cash flow metrics are reduced in the bank’s outlook as well. Cash flow from operations is expected at CHF1.39 billion in 2026, compared with CHF1.51 billion in 2025, and free cash flow to equity is forecast to fall to CHF1.05 billion from CHF1.21 billion. Net debt is projected to decline to CHF3.38 billion from CHF3.68 billion.
Despite the weaker sales outlook, Berenberg models a modest increase in shareholder payout, forecasting a dividend per share of CHF74 in 2026, up from CHF72 in 2025, implying a dividend yield of roughly 2.8% under its assumptions.
Market reaction and final observations
Berenberg’s downgrade comes as Givaudan’s shares have fallen approximately 13% since the start of March, a move that the report describes as larger than the earnings downgrade itself. In its commentary the bank summed up the primary vulnerability succinctly: "Fine Fragrances growth most at risk."
The updated forecasts and valuation assumptions reflect Berenberg’s view that near-term sales will be dampened by regional demand weakness, with more limited effects anticipated across broader, more necessity-oriented categories. The firm’s higher discount rate and marginal EPS reduction combine to underpin the move to a Hold recommendation and the lower price target.